234081-75-5

Usage

Uses

Used in Pharmaceutical Industry:
4-[1,4]Diazepan-1-yl-benzoic acid ethyl ester is used as a pharmaceutical ingredient for the production of diazepam-based medications. Its sedative, hypnotic, and muscle relaxant properties make it suitable for treating anxiety, muscle spasms, and seizures.
Used in Research Applications:
4-[1,4]Diazepan-1-yl-benzoic acid ethyl ester is also used in research for studying benzodiazepines and their effects on the central nervous system. This helps in understanding the mechanisms of action and potential therapeutic applications of benzodiazepine-based medications.

InChI:InChI=1/C14H20N2O2/c1-2-18-14(17)12-4-6-13(7-5-12)16-10-3-8-15-9-11-16/h4-7,15H,2-3,8-11H2,1H3

Upstream product

• 505-66-8 1,4-Diazacycloheptane 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 1428556-65-3 tert-butyl 4-(4-(ethoxycarbonyl)phenyl)-1,4-diazepane-1-carboxylate 
• 112275-50-0 tert-butyl 1,4-diazepine-1-carboxylate 

Downstream Products

• 234081-77-7 ethyl 4-{4-(pyrimidin-2-yl)-[1,4]diazepan-1-yl}benzoate 
• 1428557-09-8 ethyl 4-[4-(3-cyano-2-thioxo-1,2-dihydropyridin-4-yl)-1,4-diazepan-1-yl]benzoate 
• 1428557-35-0 C₂₂H₂₅N₅O₃S 
• 1428557-46-3 C₂₀H₂₁N₅O₃S 
• 1035271-61-4 ethyl 4-(4-cyclopropyl-1,4-diazepan-1-yl)benzoate 
• 1035271-65-8 ethyl 4-(4-ethyl-1,4-diazepan-1-yl)benzoate 
• 1035271-60-3 ethyl 4-(4-allyl-1,4-diazepan-1-yl)benzoate 
• 234080-75-2 tert-butyl (2S)-benzenesulfonylamino-3-[4-{4-(pyrimidin-2-yl)-[1,4]diazepan-1-yl}benzoylamino]propionate 
• 234080-76-3 (2S)-benzenesulfonylamino-3-[4-{4-(pyrimidin-2-yl)-[1,4]diazepan-1-yl}benzoylamino]propionic acid 
• 234081-79-9 4-{4-(pyrimidin-2-yl)-[1,4]diazepan-1-yl}benzoic acid 

Relevant academic research and scientific papers

BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY

Disclosed herein are bicyclic pyridines, such as thienopyridine, pyrrolopyridine, furopyridine compounds, and methods for treating cancers. The method may comprise administering a therapeutically effective amount of any of the compositions described herei

Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents

A cell-based assay was performed for the discovery of novel bone anabolic agents. Alkaline phosphatase (ALPase) activity of ST2 cells was utilized as an indicator of osteoblastic differentiation, and thienopyridine derivative 1 was identified as a hit compound. 3-Aminothieno[2,3-b]pyridine-2-carboxamide was confirmed to be a necessary core structure for the enhancement of ALPase activity, and then optimization of the C4-substituent on the thienopyridine ring was carried out. Introduction of cyclic amino groups to the C4-position of the thienopyridine ring improved the activity. Especially, N-phenyl-homopiperazine derivatives were found to be strong enhancers of ALPase among this new series. Furthermore, 3-amino-4-(4-phenyl-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2- carboxamide (15k) was orally administered to ovariectomized (OVX) rats over 6 weeks for evaluating the effects on areal bone mineral density (aBMD), and statistically significant improvements in aBMD were observed from the dosage of 10 mg/kg/day.

NOVEL COMPOUNDS

There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 1: Design and synthesis of a lead compound exhibiting αvβ3/ αIIbβ3 dual antagonistic activity

In order to generate novel compounds with integrin α vβ3-antagonistic activity together with antiplatelet activity, tricyclic pharmacophore-based molecules were designed and synthesized. Although piperazine-containing compounds initially prepared were selective αIIbβ3 antagonists, replacement of piperazine with piperidine furnished a potent αvβ3/ αIIbβ3 dual antagonist. Structure-activity relationship (SAR) studies provided clues for further development of tricyclic pharmacophore-based integrin antagonists.

Phenylpiperazine derivatives as integrin αvβ3 antagonists

An objective of the present invention is to provide compounds having integrin αvβ3 antagonistic activity, GP IIb/IIIa antagonistic activity, and/or human platelet aggregation inhibitory activity, and therapeutic agents for treating integrin αvβ3-mediated diseases and for inhibiting platelet aggregation. The derivatives according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein A represents a five- to seven-membered heterocyclic ring containing two nitrogen atoms or the like; X and Z represent CH or a nitrogen atom; R4 and R5 represent alkyl, halogen or the like; Q represents >C=O, >CH2 or the like; R6 represents H, alkyl, aralkyl or the like; R7 represents H, alkynyl or the like; R8 represents H, substituted amino or the like; R9 represents H or alkyl; m is 0 to 5; n is 0 to 4; p is 2 or 3; and q is 0 or 1.